A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances


David J. Kwiatkowski, a professor of medicine at Harvard University and an oncologist specializing in thoracic oncology at Dana-Farber Cancer Institute in Boston, was responsible for explaining the advances in genetics and clinical trials being conducted to combat the disease Yesterday, a group of lymphangioleiomyomatosis (LAM) patients attended a talk in the hall Pau Viladiu of the ICO L’Hospitalet by David J. Kwiatkowski, professor of medicine at Harvard University and oncologist specialized in thoracic oncology at the Dana-Farber Cancer Institute of Boston. He explained the different advances in genetics and clinical trials that are being carryied out to fight the disease. Those attending the event were received by the director general of the ICO, Candela Calle; by the director of IDIBELL, Gabriel Capellà, and the director of the ICO-IDIBELL ProCure Program, Miguel Ángel Pujana.

The Spanish Association of Lymphangioleiomyomatosis (AELAM) signed an agreement with ICO in 2015 to carry out a strategic collaboration to screen new therapeutic strategies for lymphangioleiomyomatosis (LAM). In this sense

AELAM has carried out several actions with the purpose of raising funds and to be able to devote them to the investigation of the disease.

What is LAM? It is a very rare lung neoplasm, of unknown cellular origin and mainly affects women, generally of childbearing age. The disease is characterized by progressive degeneration of the lungs due to invasion of metastatic cells, which may eventually require organ transplantation. It is a disease without a cure and, therefore, it is necessary to promote its research and seek solutions. That is why AELAM carries out several fundraising actions be able to support research on the disease.

Scroll to Top